(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 72.25%.
Longeveron's earnings in 2026 is -$22,388,000.On average, 4 Wall Street analysts forecast LGVN's earnings for 2026 to be -$24,773,809, with the lowest LGVN earnings forecast at -$23,802,287, and the highest LGVN earnings forecast at -$25,502,450. On average, 4 Wall Street analysts forecast LGVN's earnings for 2027 to be -$19,956,679, with the lowest LGVN earnings forecast at -$19,174,065, and the highest LGVN earnings forecast at -$20,543,641.
In 2028, LGVN is forecast to generate -$19,268,518 in earnings, with the lowest earnings forecast at -$18,512,890 and the highest earnings forecast at -$19,835,239.